Bed Rest for Idiopathic Sudden Sensorineural Hearing Loss
sudden sensorineural hearing loss:
- idiopathic in most cases
- 5-20/100,000 new cases annually in the U.S
- no establishes pathogenesis
- treated with oral steroids in most cases
- ~50% improvement in hearing levels
- bed rest - acceptable treatment, not well investigated
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Eldar Carmel, MD
- Phone Number: 972-3-5302442
- Email: eldarca@sheba.health.gov.il
Study Locations
-
-
-
Tel Hashomer, Israel
- Recruiting
- Sheba medical center
-
Contact:
- Eldar Carmel, MD
- Phone Number: 972-3-5302442
- Email: eldarca@sheba.health.gov.il
-
Principal Investigator:
- Eldar Carmel, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients with sudden sensorineural hearing loss
Exclusion Criteria:
- age less than 16 years
- contraindication for oral steroid treatment
- prior steroid treatment for hearing loss
- pregnent women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
hearing improvement
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Eldar Carmel, MD, Sheba medical center
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Otorhinolaryngologic Diseases
- Ear Diseases
- Sensation Disorders
- Hearing Disorders
- Hearing Loss
- Deafness
- Hearing Loss, Sensorineural
- Hearing Loss, Sudden
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Prednisone
Other Study ID Numbers
Other Study ID Numbers
- SHEBA-06-4065-EC-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.